<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800666</url>
  </required_header>
  <id_info>
    <org_study_id>202103102</org_study_id>
    <nct_id>NCT04800666</nct_id>
  </id_info>
  <brief_title>Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis</brief_title>
  <official_title>Effect of Stellate Ganglion Block Combined With Facial Nerve Block on the Treatment of Idiopathic Facial Paralysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Peripheral facial palsy is caused by damage to the facial nerve at any site of the peripheral&#xD;
      branches after the facial nucleus.Stellate ganglion block is performed to treat peripheral&#xD;
      facial palsy because it increases blood flow and promotes nerve regeneration.Facial Nerve&#xD;
      Block worked with elimination of local inflammation of nerve and oppression. Facial nerve&#xD;
      block is a treatment that inject drugs into the damaged nerve around to eliminate local&#xD;
      inflammation and compression of the nerve.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline House-Brackmann</measure>
    <time_frame>Baseline ,change from baseline House-Brackmann at 3 days,6 days,9 days,14 days,one month,two month</time_frame>
    <description>The House-Brackmann scale is a nerve grading system developed in 1985 by Los Angeles otolaryngologists Dr. John W. House and Dr. Derald E. Brackmann. It is used to characterize the severity of a facial paralysis patient's symptoms.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline Sunnybrook</measure>
    <time_frame>Baseline,change from baseline Sunnybrook at 3 days,6 days,9 days,14 days, one month,two month</time_frame>
    <description>Sunnybrook is a new facial nerve function of subjective assessment system.It is based on both static and dynamic aspects.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Peripheral Facial Palsy</condition>
  <arm_group>
    <arm_group_label>Facial Nerve Block Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial Nerve Block and oral Mecobalamin Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stellate Ganglion Block Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial Nerve Block and Stellate Ganglion Block and oral Mecobalamin Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Facial Nerve Block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>control</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stellate Ganglion Block</intervention_name>
    <description>Patients underwent a stellate-ganglion block at the anterolateral aspect of the C6 vertebra. After local analgesia (lidocaine 2%), a 22-gauge Quincke needle was placed in the anterolateral aspect of the C6 vertebral body. When the needle contacted the bone, it was drawn back 1 mm. 5 mL of 0·5% ropivacaine was subsequently injected next to the stellate ganglion to produce a sympathetic block.The effect of the stellate-ganglion block on the sympathetic nervous system was confirmed by the presence of Horner's syndrome (ie, facial anhydrosis, enophthalmos, ptosis, swelling of the lower eyelid, miosis, and blood-shot conjunctiva), and an increase in the temperature of the right hand of at least 2°F from baseline.</description>
    <arm_group_label>Stellate Ganglion Block Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Facial Nerve Block</intervention_name>
    <description>Operator touching the location of the mastoid, in the external auditory canal just below the front of the mastoid vertical needling.When touch the surface of the mastoid,adjust the needle across the front of the mastoid then slow needling about 1cm.The pin located below the stylomastoid foramen, and then injected drugs 5mL ( mecobalamin injection 1mg；lidocaine 60mg； dexamethasone 10mg )</description>
    <arm_group_label>D Group</arm_group_label>
    <arm_group_label>Facial Nerve Block Group</arm_group_label>
    <arm_group_label>Stellate Ganglion Block Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mecobalamin Tablets</intervention_name>
    <description>oral Mecobalamin Tablets tid-8</description>
    <arm_group_label>C Group</arm_group_label>
    <arm_group_label>Facial Nerve Block Group</arm_group_label>
    <arm_group_label>Stellate Ganglion Block Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Diagnosed by clinical and neurological assessment as one-sided simple facial&#xD;
&#xD;
          -  Age 18 to 70 ASA Ⅰ~Ⅲ&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coagulation dysfunction plate plate plate shape, quantity or abnormal function mental&#xD;
             system diseases Gillan-Bahrain syndrome cancer, mumps, shingles infection, jaw facial&#xD;
             pus lymph nodeitis, encephalitis, cerebral hemorrhage and other diseases Local&#xD;
             infection or systemic infectious disease at the puncture site ASA rating greater than&#xD;
             III. fail accept to nerve block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>zhuan zhang, professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>the Affiliated Hospital of Yangzhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>zhuan zhang, professor</last_name>
    <phone>+8615062791355</phone>
    <email>zhangzhuancg@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>zhuan zhang, professor</last_name>
      <phone>+8615062791355</phone>
      <phone_ext>+8615062791355</phone_ext>
      <email>zhangzhuancg@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>March 13, 2021</last_update_submitted>
  <last_update_submitted_qc>March 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Peripheral Facial Palsy</keyword>
  <keyword>Stellate Ganglion Block</keyword>
  <keyword>Facial Nerve Block</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bell Palsy</mesh_term>
    <mesh_term>Ganglion Cysts</mesh_term>
    <mesh_term>Facial Paralysis</mesh_term>
    <mesh_term>Paralysis</mesh_term>
    <mesh_term>Facies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

